Sökning: onr:"swepub:oai:gup.ub.gu.se/74298" >
Irinotecan plus car...
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
-
Hermes, Andreas (författare)
-
- Bergman, Bengt, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
Bremnes, Roy (författare)
-
visa fler...
-
- Ek, Lars (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
Fluge, Sverre (författare)
-
Sederholm, Christer (författare)
-
Sundstrøm, Stein (författare)
-
Thaning, Lars (författare)
-
Vilsvik, Jan (författare)
-
Aasebø, Ulf (författare)
-
Sörenson, Sverre (författare)
-
visa färre...
-
(creator_code:org_t)
- 2008
- 2008
- Engelska.
-
Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 26:26, s. 4261-7
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: A Japanese randomized trial showed superior survival for patients with extensive-disease (ED) small-cell lung cancer (SCLC) receiving irinotecan plus cisplatin compared with etoposide plus cisplatin. The present trial evaluated the efficacy of irinotecan plus carboplatin (IC) compared with oral etoposide plus carboplatin (EC). PATIENTS AND METHODS: Patients with ED SCLC were randomly assigned to receive either IC, which consisted of carboplatin (area under the curve = 4; Chatelut formula) and irinotecan (175 mg/m2) intravenously both on day 1, or EC, which consisted of carboplatin as in IC and etoposide (120 mg/m(2)/d) orally on days 1 through 5. Courses were repeated every 3 weeks with four cycles planned. Doses were reduced by one third in patients with a WHO performance status (PS) of 3 to 4 and/or age older than 70 years. Primary end point was overall survival (OS). Secondary end points were quality of life (QOL) and complete response (CR) rate. RESULTS: Of 220 randomly assigned patients, 209 were eligible for analysis (IC, n = 105; EC, n = 104). Thirty-five percent were older than 70 years, and 47% had a PS of 2 to 4. The groups were well balanced with respect to prognostic factors. OS was inferior in the EC group (hazard ratio = 1.41; 95% CI, 1.06 to 1.87; P = .02). Median survival time was 8.5 months for IC compared with 7.1 months for EC. One-year survival rate was 34% for IC and 24% for EC. CR was seen in 18 IC patients compared with seven EC patients (P = .02). There were no statistically significant differences in hematologic grade 3 or 4 toxicity. Grade 3 or 4 diarrhea was more common in the IC group. QOL differences were small, with a trend toward prolonged palliation with the IC regimen. CONCLUSION: IC prolongs survival in ED SCLC with slightly better scores for QOL.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Aged
- Aged
- 80 and over
- Antineoplastic Combined Chemotherapy Protocols
- administration & dosage
- Camptothecin
- administration & dosage
- analogs & derivatives
- Carboplatin
- administration & dosage
- Carcinoma
- Small Cell
- drug therapy
- Etoposide
- administration & dosage
- Female
- Humans
- Lung Neoplasms
- drug therapy
- Male
- Middle Aged
- Prognosis
- Survival Analysis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Hermes, Andreas
-
Bergman, Bengt, ...
-
Bremnes, Roy
-
Ek, Lars
-
Fluge, Sverre
-
Sederholm, Chris ...
-
visa fler...
-
Sundstrøm, Stein
-
Thaning, Lars
-
Vilsvik, Jan
-
Aasebø, Ulf
-
Sörenson, Sverre
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Lungmedicin och ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Journal of clini ...
- Av lärosätet
-
Göteborgs universitet
-
Lunds universitet